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Pharmacological manipulations to purge human immunodeﬁciency virus (HIV) from latent reser-
voirs have been considered as an adjuvant therapeutic approach to highly-active antiretroviral ther-
apy for the eradication of HIV. Our novel histone deacetylase inhibitor NCH-51 induced expression
of latent HIV-1 with minimal cytotoxicity. Using chromatin immunoprecipitation assays, we
observed a reduction of HDAC1 occupancy, histone hyperacetylation and the recruitment of positive
transcription factors at the HIV-1 promoter in latently infected-cells under the treatment with NCH-
51. Mutation studies of the long terminal repeat (LTR) revealed NCH-51 mediated gene expression
through the Sp1 sites. When Sp1 expression was knocked-down by small interfering RNA, the
NCH-51-mediated activation of a stably integrated HIV-1 LTR was attenuated. Moreover, the Sp1
inhibitor mithramycin A abolished the effects of NCH-51.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The persistence of cellular reservoirs containing proviruses of
human immunodeﬁciency virus type I (HIV-1) despite prolonged
treatment with highly active antiretroviral therapy (HAART) repre-
sents the major obstacle in the eradication of HIV. These latently
infected cells are permanent sources of viral reactivation and lead
to a rebound of the virus load after interruption of HAART [1–4].
Resting memory CD4+ T cells or macrophages lacking proviral gene
expression carry an integrated and transcriptionally silent provirus
[1,2,5,6].
Restrictive chromatin structures at the HIV-1 long terminal re-
peat (LTR) contribute to transcriptional silencing leading to la-
tency. The nucleosomal structure, nuc-1, near the viral mRNA
start site plays regulatory roles in inducing LTR-driven transcrip-
tion [7,11]. The compaction of the chromatin during HIV-1 proviral
latency and its reversion to a permissive state is directly governed
by posttranslational modiﬁcations such as acetylation, phosphory-
lation and methylation [1,2,7–11].chemical Societies. Published by E
olecular and Cellular Biology,
iences, 1 Kawasumi, Mizuho-
+81 52 859 1235.
. Okamoto).Histone deacetylases (HDACs) have been known to be critical
regulators of HIV-1 latency. Accumulated evidence has demon-
strated that presence of HDAC1 leads to the repression of HIV-1
LTR, whereas inhibition of HDAC1 results in HIV gene expression
[7,11–13]. To date, HDAC1 has been reported to be recruited to
the HIV-1 LTR by the NF-jB p50 homodimer, CBF-1 protein, or
through binding with complexes containing transcription factors
such as YY1, LSF, c-myc and Sp1 [12–16]. We also reported that
activator protein 4 (AP-4) acts as a transcriptional repressor by
recruiting HDAC molecules and is involved in maintaining viral la-
tency [7].
HDACs have been considered potential targets in the new ther-
apeutic approach against HIV-1 infection because HDAC inhibition
results in promoter activation and purges HIV-1 from its latent
stage. It has been perceived that inducing viral outgrowth of
HIV-1 from persistently infected reservoirs would allow complete
eradication of chronic viral infection by the immune system and
HAART [1,2]. Previous observations have shown that HDAC inhibi-
tors (HDACis) such as trichostatin A (TSA) and valproic acid (VPA)
[2,11,16] are capable of inducing HIV-1 transcription in latently in-
fected cells. Similarly, the FDA-approved drug suberoylanilide
hydroxamic acid (SAHA), prescribed for the treatment of cutaneous
lymphoma, has also been reported to have successfully reactivated
HIV-1 replication from the resting CD4+ T cells and peripherallsevier B.V. All rights reserved.
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infected patients [17–19]. However, recent studies have reported
that administration of VPA with intensiﬁed ART showed limited ef-
fects in reducing the latently-infected resting CD4+ T cells or ablat-
ing intermittent and low-level viremia [20–23].
In spite of the reported lack of clinical success with VPA, re-
search on this class of agents is still necessary with the goal of
developing better therapeutically relevant drugs that can be inte-
grated in a regimen to deplete latent infection. In this study, we
examined the effect of novel HDACi NCH-51 on HIV-1 gene expres-
sion in latently infected OM10.1 cells. This compound was de-
signed based on the structure of SAHA by replacement of the
hydroxamic acid group with acylated thiol group in order to obtain
better pharmacokinetics and less toxicity [24]. NCH-51 could inhi-
bit HDACs as strongly as SAHA and inhibited the cell growth of var-
ious lymphoid malignant cells and solid tumor cell lines in vitro
[24,25]. Here we demonstrate that NCH-51 augmented the HIV-1
production in latently infected OM10.1 cells and such reactivation
is associated with a loss of HDAC1 occupancy and subsequent
hyperacetylation of histones in nuc-1 at the HIV-1 promoter.
2. Materials and methods
2.1. Cell culture
OM10.1, a derivative of the HL-60 myelomonocytic leukemic
cell line containing a single integrated copy of HIV-1LAV provirus
[26], and ACH-2, a chronically HIV-1-infected T cell line derived
from the parent cell line A3.01 [27,28], were maintained at 37 C
in RPMI 1640 (Sigma) with 10% heat-inactivated fetal bovine ser-O
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Fig. 1. Screening of the effect of HDAC inhibitors on HIV-1 production. (A) Chemical stru
latently infected with HIV-1. Cells were incubated with various HDACis or TNF-a. The cel
were performed in triplicates. The means ± S.D. values are indicated. NaB, sodium butyrum (Sigma), penicillin (100 units/ml), and streptomycin (100 mg/
ml). To maintain the latency of the HIV-1 in OM10.1 and ACH-2
cells, 20 lM AZT was added in the culture medium and was ex-
cluded prior to experiments [29]. 293 cells and TZM-bl cells, a
HeLa-derived cell line expressing surface CD4, CXCR4, CCR5 and
containing a chromatin-integrated HIV-1 LTR [10,19,30,31], were
grown at 37 C in Dulbecco’s modiﬁed Eagle’s medium (Sigma)
with supplements.
2.2. Reagents
The synthesis and HDACi activities of NCH-47 and NCH-51 were
reported previously [24]. Sodium butyrate (NaB) was purchased
from Sigma. Human recombinant TNF-a was purchased from
Roche and used at 1.0 ng/ml for NF-jB stimulation. Antibodies
for HDAC1, Sp1 acetyl-lysine and acetylated form of human his-
tone H3 were obtained from Upstate Biotech, anti-RNA Pol II and
normal rabbit anti-IgG were from Santa Cruz Biotechnology (Santa
Cruz, CA), while anti-AP-4 antibody was obtained as previously de-
scribed [7]. Mithramycin A was purchased from Sigma.
2.3. Plasmids
Construction of HIV-1 LTR-based luciferase expression plas-
mids, wild type (WT) HIV-1 LTR-Luc (containing the HIV-1 LTR
U3 and R), its 50 truncated mutant CD52-Luc (117) and CD23-
Luc (65), and NF-jB mutant HIV-1 LTR-Luc, where NF-jB sites
were mutated in WT HIV-1 LTR-Luc, were done as previously de-
scribed [32,33]. Sp1 mutant HIV-1 LTR-Luc plasmid was generated
by PCR with WT HIV-1 LTR-Luc DNA as a template and the threeIC50 in vitro (nM)
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Fig. 2. Effect of NCH-51 on HIV-1 latently/chronically infected cells. (A and B) NCH-51 stimulated HIV-1 production in OM10.1 and ACH-2 cells. OM10.1/ACH-2 cells were
treated with NCH-51 for 4 h then exposed to TNF-a (1 ng/ml) for 24 h. Culture supernatants were then collected and assessed for HIV-1 viral p24 antigen determination. (A
and B, bottom panels) Cytotoxicity of NCH-51 on OM10.1 and ACH-2 cells. The data are means ± S.D. values of triplicate experiments.
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79) were changed to TT using site-directed mutagenesis as de-
scribed [7].
2.4. Viral replication assay
The stimulatory effect of HDAC inhibitors in latently infected
cells was evaluated based on the extent of activation of HIV-1 viral
p24 core antigen production in OM10.1 cells as previously de-
scribed [7,33]. Brieﬂy, cells were treated with or without NCH-47or NCH-51 for 4 h then stimulated with or without TNF-a for
24 h at 37 C. The culture supernatants were then collected and as-
sayed for viral p24 antigen using the commercially available Retro-
tek HIV-1 p24 antigen enzyme-linked immunosorbent assay
(ELISA) kit (Cellular Products, Buffalo, NY). The cytotoxicity of the
test compounds was measured by WST-1 method (Roche) [33].
Fifty percent cytotoxic concentration (CC50) was deﬁned as the
compound concentration that reduced cell viability by 50%. In an-
other experiment, OM10.1 cells were pretreated with varying con-
centrations of mithramycin A for 2 h and then stimulated with
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Fig. 3. NCH-51 increases acetylation of nuc-1 and decreases occupancy of HDAC1 at the HIV-1 LTR. (A) OM10.1 cells were treated with the desired concentrations of NCH-51
for 24 h and cell lysates were collected and subjected to Western blotting. Protein concentration was determined to ensure equal loading of proteins. (B) Recruitment of
transcription factors and the acetylation of histones at the HIV-1 LTR. OM10.1 cells treated with or without NCH-51 (1.6 lM) were assayed by chromatin
immunoprecipitation with designated antibodies. Input DNA (input) represents 10% of total input chromatin DNA while immunoprecipitation with IgG serves as a negative
control. (C) Effects of novobiocin on the NCH-51-mediated HIV-1 production. OM10.1 cells were pretreated with novobiocin (100 and 200 lg/ml), a topoisomerase DNA II
inhibitor, for 1 h and then stimulated with NCH-51 (1.6 lM) for an additional 24 h. Viral production was assessed as described in Section 2. The data are means ± S.D. of
triplicate experiments.
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scribed above.
2.5. Transfection and luciferase assay
Transfections were carried out in 293 cells (0.1 lg plasmid
DNAs) and Jurkat T cells (0.3 lg plasmid DNAs) using Fugene 6
Transfection Reagent (Roche Applied Science) and Lipofectamine
LTX (Invitrogen) according to the manufacturer’s instructions,
respectively. HIV-1 LTR-based reporter plasmids described above
were transfected for 24 h and then treated with NCH-51 (1.6 lM)
or TNF-a (5 ng/ml), as a positive control, for an additional 12 or
24 h. Transfected cells were harvested and the extracts were sub-
jected to luciferase assay using the Luciferase Assay System (Pro-
mega). Luciferase activity was normalized with protein
concentration. Protein concentration was measured with BCA pro-
tein assay kit (PIERCE).
2.6. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as previously described [7,8,33].
Brieﬂy, OM10.1 cells were cross-linked with formaldehyde for
10 min at 37 C and reaction was stopped with 125 mM glycine.
Cells were lysed and the cross-linked chromatin was sheared by
sonication 10 times for 30 s each time at the maximum power with30 s of cooling on ice between pulses (Bioruptor; COSMO Bio,
Tokyo). Sheared chromatin fractionswere collected and pre-cleared
with salmon sperm DNA protein G-agarose beads (Upstate Biotech)
for 1 h. Immunoprecipitation was then carried out with the desired
antibodies overnight at 4 C with rotation. The immuno-precipi-
tates were collected using lMACS magnetic beads (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) and washed sequentially
with speciﬁed buffers. Immune complexes were eluted, reverse
cross-linked at 65 C for 5 h and treated with proteinase K at
45 C for 1 h. DNA was puriﬁed by QIAquick PCR puriﬁcation kit
(Qiagen) according to the manufacturer’s protocol. PCR (31–33 cy-
cles) was performed as follows: denaturation at 94 C for 1 min,
annealing at 55 C for 30 s and extension at 72 C for 30 s. The pri-
mer sequences used for PCR spanning 109 to +79 nucleotides
within HIV-1 LTR were the following: forward (50-TAC AAG GGA
CTT TCC GCT GG-30) and reverse (50-TTG AGG CTT AAG CAG TGG
G-30) [7]. For each reaction, 10% of the original sheared chromatin
DNA was similarly reverse-crosslinked, puriﬁed, and the recovered
DNA was used as input control.
2.7. siRNA transfection
The short interference (si)RNAs against Sp1 and control gfp
were purchased from Santa Cruz Biotechnology Inc. and Dharm-
acon, respectively. TZM-bl cells were cultured in 24-well plates
AB
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Fig. 4. NCH-51 activates transiently transfected HIV-1 LTR. (A) A schematic diagram of the WT HIV-1 LTR-based reporter plasmids used in determining the contribution of
various portions of the HIV-1 promoter. (B and C) The HIV-1 LTR promoter constructs described in A were transiently transfected in 293 cells and Jurkat T cells, treated with
NCH-51 as described in Section 2, and harvested for luciferase assay. Luciferase activity was normalized by the protein concentration of the lysate. The data are means ± S.D.
of triplicate experiments.
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agent according to the manufacturer’s instructions (Invitrogen)
and incubated for 48 h. To ensure the knockdown of Sp1 protein,Western blotting was performed with anti-Sp1 antibody. The
transfected cells were harvested and subjected to luciferase
assay.
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3.1. NCH-51 activates HIV-1 production in latently infected cells
HDAC inhibitors induce acetylation of histones consequently
propelling the activation of gene transcription. To assess whether
our novel HDACis, NCH-47 and NCH-51, can activate the latent
HIV-1 proviruses in infected cells, we initially tested these com-
pounds in OM10.1 cells as well as other known HDACis such as
SAHA, NaB and TSA (Fig. 1B). Strikingly, although there is a little
difference in the structures of NCH-47 and NCH-51, we found that
NCH-51 markedly augmented HIV-1 production compared with
NCH-47. The effect of NCH-51 was even greater than other known
HDACis such as SAHA, NaB and TSA at tested concentrations. Thus,
we investigated further the activity of NCH-51 in the following
experiments.
As shown in Fig. 2A, treatment with NCH-51 alone induced the
production of HIV-1 in OM10.1 cells. This effect was further aug-
mented by TNF-a. We performed similar experiments using ACH-
2 cells, a chronically HIV-1-infected T cell line, and found that
NCH-51 could upregulate virus production in these cells as well
(Fig. 2B). At the concentrations tested, 48 h incubation with NCH-
51 elicited a slightly higher cell death in ACH2 than OM10.1 cells
(Fig. 2A and B, bottom panels). CC50 values for both cell lines were
estimated to be approximately 2 lM. These results demonstrate
that NCH-51 can efﬁciently reactivate expression of HIV-1 from
latently/chronically infected cells under non-cytotoxic
concentrations.3.2. NCH-51 facilitates HIV-1 replication through chromatin
remodeling
Transcriptional silencing during HIV-1 latency is controlled by
the local environment of the integrated virus as well as the pres-
ence of other activating or repressing viral or host factors [34]. Ini-
tially, we examined the histone acetylation state of whole cell
lysates from OM10.1 cells. As demonstrated in Fig. 3A, NCH-51
treatment increased the acetylation of histone H3 at either K9 or
K14 in a dose-dependent manner. To conﬁrm this observation,
we employed a chromatin immunoprecipitation assay (Fig. 3B).
Consistent with results obtained by Western blotting, hyperacety-
lation of histone H3 at nuc-1 region of the HIV-1 LTR occurred
upon NCH-51 treatment with simultaneous depletion of HDAC1
occupancy. In addition, assessment of the differential recruitment
of other transcription factors revealed an enrichment of positive
transcription factors such as RNA polymerase II and TBP (TFIID),
whereas the negative transcription factor AP-4 was abolished.
NCH-51 treatment of TZM-bl cells [10,19] containing chromatin-
integrated HIV-1 LTR yielded similar results (data not shown).
We then examined whether the NCH-51-induced HIV-1 virus
production in OM10.1 cells would be abrogated by the topoisomer-
ase II inhibitor, novobiocin [35]. Topoisomerase II is a nuclear ma-
trix-associated enzyme that cleaves and religates dsDNA, an event
required for the structural reorganization of nuclear chromatin,
and thus plays an essential role in the effects of HDACi [35]. As
demonstrated in Fig. 3C, we found that the virus production
induced by NCH-51 in OM10.1 cells was inhibited by novobiocin
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structure and promoted HIV reactivation.
Overall, these results show that the induction of viral replica-
tion from latently infected OM10.1 cells by NCH-51 correlates with
the hyperacetylation of histones and the simultaneous removal of
HDAC1 on the HIV-1 promoter.
3.3. NCH-51 activates transcription from HIV-1 LTR
SAHA was previously reported to induce HIV-1 transcription
[17–19]. To determine whether NCH-51 activates transcription
from HIV-1 LTR, we generated various plasmid constructs, as
shown in Fig. 4A, transiently transfected them into 293 cells and
determined the levels of HIV-1 gene expression by luciferase assay.
NCH-51 stimulated wild type (WT) HIV-1 LTR expression as
well as the CD23-Luc HIV-1 LTR promoter (Fig. 4B). When NF-jB
binding sites in the LTR were absent (CD52-Luc) or mutated (NF-
jB mut HIV-1 LTR-Luc), a marked transcriptional activation by
NCH-51 was still observed whereas it totally abolished the effects
of TNF-a. (Fig. 4B, top right and bottom left panel). We thus spec-
ulated that Sp1 might be accountable for the reactivation potential
of NCH-51 because of the reported role of Sp1 sites for transcrip-
tional activation of HIV-1 LTR by another HDACi valproic acid[36]. Thus, we created a plasmid construct of HIV-1 LTR with all
three Sp1 binding sites mutated (Fig. 4C, bottom right). Indeed, de-
spite the presence of intact NF-jB binding sites, the mutation of all
Sp1 binding sites severely weakened the effects of NCH-51. A sim-
ilar effect by NCH-51 was observed using Jurkat T cells (Fig. 4C).
We noted that longer exposure (24 h) to NCH-51 promoted higher
transcriptional activity of the HIV-1 LTR. Meanwhile, we also ob-
served that TNF-a stimulation caused higher promoter activation
in Sp1-mutant HIV-1 LTR than the wild type (Fig. 4C, ﬁrst and
right-bottom panel), indicating that without Sp1 sites transcription
is carried out mainly by the NF-jB elements. These ﬁndings indi-
cate that Sp1 appears to be crucial in the transcriptional activation
of HIV-1 LTR by NCH-51.
3.4. The effect of Sp1 knockdown
To examine the effect of endogenous Sp1, TZM-bl cells, contain-
ing a stable chromosomally-integrated HIV-1 LTR, were treated
with a siRNA designed to knock-down Sp1 gene expression. Trans-
fection with 50 nM Sp1 siRNA markedly reduced but did not com-
pletely deplete Sp1 protein expression, most likely because Sp1 is
ubiquitously expressed (Fig. 5A). Sp1 siRNA treatment, however,
signiﬁcantly suppressed the effects of NCH-51 in inducing the tran-
1110 A.F.B. Victoriano et al. / FEBS Letters 585 (2011) 1103–1111scriptional activity of the HIV-1 LTR promoter, as shown in Fig. 5B
(1.8 compared to 4.3 with control siRNA). To evaluate further
the involvement of Sp1 in the NCH-51-mediated activation, we
treated OM10.1 cells with varying concentrations of mithramycin
A, an Sp1 antagonist [38]. We found that mithramycin A inhibited
the HIV-1 p24 expression induced by NCH-51 (Fig. 5C), thus indi-
cating the importance of Sp1 for this response.
4. Discussion
Despite advances in HAART, the presence of drug-inaccessible
sanctuaries that harbor latent proviruses impedes HIV eradication.
An alternative approach of inducing the expression of quiescent
HIV-1 proviral genomes, but has limited activating effects, has been
sought with the prospect that it will allow expression of latent HIV
and avoid the pitfalls of global T-cell activation [1,2,23,36]. This
clinical strategy has been initiated by Lehrman et al. [37] using
the combination of the HDACi valproic acid with intensiﬁed HAART
and was found successful in accelerating the clearance of HIV-1-in-
fected cell population from resting CD4+ T cells in HIV-1 infected
patients. Since then, many have continuously searched for the
appropriate pharmacological activator(s) and/or combinatorial
drug regimen that may efﬁciently deplete latent reservoirs.
We provide additional evidence demonstrating the efﬁcacy of
HDACi NCH-51 in reactivating HIV-1 replication in latently/chron-
ically infected cells such as OM10.1 and ACH-2. This compound has
been shown to have better pharmacokinetics and less cytotoxicity
than the parent compound SAHA [20]. NCH-51 could clearly upreg-
ulate gene expression from a latently infected HIV provirus by a
mechanism, though not fully elucidated yet in our system, which
considerably utilizes the Sp1 sites and the removal of the constitu-
tively associated repressors (e.g., HDAC1 and AP-4) and the subse-
quent recruitment of positive transcription factors (e.g., p65, TFIID
and p300) to the HIV-1 promoter region.
The nucleosome nuc-1, immediately downstream of the tran-
scription start site of proviral HIV-1, plays a crucial role in the gen-
eration of post-integration latency. Nuc-1 is in a hypoacetylated
state exhibiting a repressive conﬁguration of the local chromatin
[2,9,11]. Such suppressive chromatin structure must be remodeled
prior to transcriptional activation by NF-jB or by other positive
transcription factors such as Tat. HDAC inhibition induces acetyla-
tion of core histones that relaxes chromatin structure, making the
DNA more accessible to the transcriptional machinery and co-acti-
vators [7,9,18,19,39]. Our ﬁndings have shown that the alteration
in the chromatin structure by NCH-51 resulted in the dynamic
recruitment of positive transcription factors and epigenetic
changes on the HIV-1 LTR promoter thereby initiating directed
transcriptional activation.
We found that Sp1 sites are considerably involved in the NCH-
51-mediated activation of the HIV-1 promoter as depicted in our
transient transfection studies and Sp1 siRNA knockdown experi-
ment. Previous studies have indicated that Sp1 sites can recruit
transcriptional repressor factors/complexes as well as activating
factors [11,13,14,40]. Sp1 appears to contribute to the proviral la-
tency by recruiting HDAC1 and/or HDAC2 [10,14,41] to the HIV-1
LTR. Treatment by NCH-51 could most likely disrupt the formation
of this repressor complex by displacing HDAC1 from the HIV-1 LTR
as evidenced in our ChIP results. Thus, in the absence of Sp1 bind-
ing sites (Fig. 4) or Sp1 protein (Fig. 5) the HDAC1 could not be re-
cruited and no effect could be observed. We also speculate that in
the latency model system that we used, the de-repression of HDAC
activity on Sp1 upon NCH-51 treatment most likely regulates Sp1
function through the consequential recruitment of transcriptional
co-activators such as p300 [42,43] and P-TEFb [44]. p300 exhibit-
ing intrinsic HAT activity could regulate the transcriptional activityof Sp1 directly or by acting as a scaffold for other co-activators of
Sp1 [34,42,43]. The enrichment of TBP/TFIID level in our ChIP assay
also suggests its direct or indirect association with Sp1 or with
other cellular proteins that are responsible for initiation of tran-
scription [7,45,46]. Moreover, NCH-51 induction might, though
not yet fully elucidated here, induce other posttranslational modi-
ﬁcations of Sp1 apart from acetylation wherein no remarkable
change was found after an hour of treatment with NCH-51 (data
not shown). This possibility needs further clariﬁcation because
posttranslational modiﬁcation of Sp1 was previously reported to
inﬂuence its protein stability and transcriptional activity [47].
The effective reactivation of latent HIV-1 gene expression by the
simultaneous treatment of NCH-51 and TNF-a suggests that our
HDACi has the potential for combinatorial therapeutics against
HIV latency. However, at present, we need to carefully evaluate
the limitations of such approach due to a possible sequential gen-
eration of viral escape mutants or uncontrolled spread of HIV-1 in
anatomic sites where HDACis can penetrate but inaccessible to
HAART. Moreover, investigations on the effect of NCH-51 on global
gene expression changes and on host genes required for HIV repli-
cation must be considered to ensure its applicability and safety.
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